Press releases 2011

Koen Janssens appointed CEO of Applied Maths

The Board of Directors of Applied Maths has appointed Koen Janssens as CEO of Applied Maths. Koen Janssens holds a Master degree in Applied Economics and a Master of Science in Bioinformatics (Katholieke Universiteit Leuven). During the last seven years, he has been increasingly involved in the operational management of the company. In his new role as CEO, he will be supported by an Executive Committee, consisting of Paul Vauterin, Director of Software Development and Bruno Pot, Director of Business Development.

New de novo assembler for next generation sequencing data in BioNumerics

Applied Maths NV today announces that it has released a new version of its flagship software suite BioNumerics that allows de novo assembly to be performed on next generation sequencing data. This new feature, available in version 6.6, consolidates the development of BioNumerics into a complete and fully integrated suite for preprocessing and analysis of NGS data.

Scientists at Applied Maths publish novel strategies to assess and improve the reliability of cluster analysis

Scientists working at Applied Maths have published a research article that describes a global statistical framework to calculate the reliability of branches on trees or networks resulting from cluster analysis, and that allows the most probable trees to be produced from a set of degenerated solutions. The article, titled “A resampling strategy for reliable network construction”, has appeared in the May 2011 issue of Molecular Phylogenetics and Evolution (MPE 60: 273-286).

CEO transition at Applied Maths

Ruth Devenyns, Chairman of the board at Applied Maths, announces that Luc Vauterin has decided to step down as CEO, effective June 1, 2011, in order to focus more on the scientific development of the company and on supporting Applied Maths’ ever expanding customer base. With immediate effect, the CEO function is being assumed by Stijn Spitaels, a former consultant at McKinsey & Company.

Bayer CropScience chooses BioNumerics as global data analysis platform

Applied Maths today announces that Bayer CropScience has decided to implement the BioNumerics platform globally for its plant breeding program. The choice for BioNumerics was incentivized by the software’s comprehensive databasing and analysis tools, enabling workers to deploy one uniform software platform for diverse projects and techniques.

CDC chooses BioNumerics to monitor HIV drug resistance in US Global Health Initiative

HIV researchers at CDC and across the globe are keeping close watch on the rapid mutations of HIV and its threat of resistance to current and novel therapies. In order to track variant, atypical and drug resistant HIV strains, smart systems are required that can rapidly process information from multiple sources into clear and reportable summarizations. Critical understanding of mutations in HIV is needed to allow physicians and public health policy makers to make treatment decisions and to create preventive measures.

Applied Maths closes partnership for optical genome mapping of MRSA

Applied Maths has entered into a partnership with 5 leading research and knowledge centers in the Netherlands to develop a methodology for the characterization of the genomic content of livestock-associated micro-organisms using the optical genome mapping technology. Optical mapping is a technology that rapidly generates high-resolution, ordered, whole genome restriction maps from single DNA molecules and is a valuable tool in understanding the genome organization, in facilitating de novo assembly, and as a portable high-resolution bacterial typing technique.

Applied Maths successfully expands its customer base

Applied Maths NV proudly announces that it has acquired a record number of new customers in 2010. The company now has an impressive customer base of over 2,300 unique organizations in 94 countries, including universities, governmental and non-profit research centers, food and quality inspection agencies, public health centers, hospitals and clinical research labs, pharmaceutical and biotech companies, food industry, etc.